Table 1 Main baseline characteristics of the included studies
From: Simultaneous versus staged bilateral total hip arthroplasty: a systematic review and meta-analysis
Author (year) | Country | Study design | Simultaneous bilateral THA | Staged bilateral THA | Mean follow-up (range) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Age (mean, year) | Gender (male/female) | BMI (mean. Kg/m2) | ASA (1/2/3/4) (percentage) | n | Age (mean, years) | Gender (male/female) | BMI (mean. Kg/m2) | ASA (1/2/3/4) (percentage) | Time interval between stages | ||||
Agarwal et al. (2016) | India | Retrospective cohort | 48 | 52 | 20:28 | – | – | 56 | 54 | 26:30 | – | – | 4.2 days | 70 (36–82 months) |
Aghayev et al. (2010) | Switzerland | Registry | 247 | 59 | 116:131 | – | – | 1572 | 62.5 | 786:786 | – | – | – | 60 months |
Alfaro-Adrián et al. (1999) | Brazil | Retrospective cohort | 95 | 65 | 40:55 | – | 43/37/19/1 | 107 | 63.9 | 42:65 | – | 60/29/8/3 | 10.1 months | – |
Berend et al. (2007) | USA | Retrospective cohort | 167 | 52.7 | 100:67 | 29.7 | – | 110 | 57.3 | 47:63 | 30.8 | – | 8.1 months | 28.5 months |
Bhan et al. (2006) | India | Randomized clinical trial | 83 | 46.6 | 54:29 | – | 59/31/10/0 | 85 | 43.4 | 51:34 | – | 64/29/6/1 | 3–7 months | 60 months |
Brown et al. (2017) | USA | Retrospective cohort | 15 | 56.9 | 8:7 | 26.4 | Mean = 1.8 ± 0.6 | 44 | 60.2 | 24:20 | 27.8 | Mean = 2.2 ± 0.6 | 0.90 ± 0.89 years | 3 months |
Calabro et al. (2020) | Australia | Registry | 2779 | – | 6214:6145** | – | 19/60/20/1 | 9580 | – | 6214:6145** | – | 10/58/30/2 | – | Minimum = 1.5 years |
Eggli et al. (1995) | Switzerland | Prospective cohort | 64 | 54 | 133:122** | – | – | 191 | 61 | 133:122** | – | – | 96 days | 1.5 years |
Garland et al. (2015) | Sweden | Registry | 1680 | – | 767:913 | 26.9 | 33/54/13/0 | 40,558 | – | 16,356:24,202 | 27.4 | 23/61/16/0 | – | to the day of death |
Goh et al. (2022) | USA | Retrospective cohort | 220 | 60.8 | 341:330Δ | 30 | – | 170 | 64 | 123:210Δ | 30.7 | – | – | 3 months |
Guo et al. (2020) | China | Retrospective cohort | 863 | 49 | 604:259 | 24.7 | 31/68/1/0 | 282 | 52.5 | 152:130 | 24.8 | 27/69/4/0 | – | Minimum = 3 months |
Hooper et al. (2009) | New Zealand | Registry | 303 | 61 | – | – | – | 743 | 61 | – | – | – | – | 6 months |
Hou et al. (2021) | China | Retrospective case control | 100 | 54 | 30:70 | 24.6 | – | 100 | 57 | 29:71 | 24.6 | – | – | – |
Houdek et al. (2017) | USA | Retrospective case control | 94 | 52.2 | 54:40 | 27.1 | 7/78/15/0 | 94 | 52.1 | 54:40 | 27.8 | 7/80/13/0 | 3Â months | 48Â months |
Inoue et al. (2021) | USA | Retrospective cohort | 256 | 58.2 | 155:101 | 27.8 | – | 387 | 62.5 | 176:211 | 28.4 | – | 31.5 months | 90 days |
Johnston et al. (2011) | Scotland | Retrospective cohort | 68 | 61.5 | 26:42 | 27.4 | – | 526 | 66.5 | 208:318 | 27.2 | – | – | 1.5 years (24–108 months) |
Kamath et al. (2016) | Switzerland | Retrospective cohort | 41 | 60.7 | 24:17 | – | 18/58/24/0 | 44 | 68.7 | 18:26 | – | 12/65/23/0 | – | Minimum = 24 months |
Kim et al. (2017) | South Korea | Retrospective cohort | 63 | 43.1 | 39:24 | 22.9 | 30/60/10/0 | 60 | 43.5 | 32:28 | 23.3 | 30/66/4/0 | 4.8Â months | 60.2Â months |
Lindberg‑Larsen et al. (2013) | Denmark | Registry | 103 | 55.7 | 59:44 | – | – | 577 | 66.9 | 234:343 | – | – | – | Max = 415 days |
Lorenze et al. (1998) | USA | Retrospective case control | 40 | – | 20:20 | – | – | 40 | – | 20:20 | – | – | – | – |
Martin et al. (2016) | Canada | Retrospective case control | 12 | 58.9 | – | 27.9 | Mean = 2.2 ± 0.4 | 12 | 63.9 | – | 26.3 | Mean = 2.2 ± 0.6 | – | – |
Mou et al. (2021) | China | Retrospective cohort | 11 | – | 10:1 | 22.7 | – | 12 | – | 10:2 | 22.7 | – | 40.8 days | 80.9 months |
Panchal et al. (2021) | India | Retrospective case control | 54 | – | 27:27 | – | – | 54 | – | 27:27 | – | – | – | 62.4 months |
Partridge et al. (2019) | UK | Registry | 2507 | 60.6 | 1178:1329 | – | – | 9915 | 65.5 | 3966:5949 | – | – | – | 3 months |
Parvizi et al. (2006) | USA | Retrospective case control | 98 | 53 | 53:45 | 28.8 | 11/72/17/0 | 98 | 65 | 46:52 | 30.2 | 1/51/48/0 | 138 days | Minimum = 6 months |
Poultsides et al. (2017) | USA | Retrospective cohort | 1946 | 56.3 | 1000:946 | – | – | 1839 | 63.1 | 746:1093 | – | – | 5–365 days | – |
Quadri et al. (2015) | Pakistan | Retrospective cohort | 34 | 39 | 30:4 | 25 | 29/57/7/7 | 14 | 42 | 6:8 | 27 | 14/57/29/0 | – | – |
Rasouli et al. (2014) | USA | National database | 14,798 | 58.4 | – | – | – | 1532 | 60.3 | – | – | – | – | – |
Reuben et al. (1998) | USA | Retrospective case control | 7 | 49 | 4:3 | – | Mean = 2.5 ± 0.5 | 8 | 57 | 1:7 | – | Mean = 1.7 ± 0.7 | – | – |
Saito et al. (2010) | Japan | Retrospective case control | 49 | 59 | 6:43 | 23.5 | – | 40 | 61.9 | 4:36 | 23.8 | – | 30.7 days | 5.5 years (24–120 months) |
Salvati et al. (1978) | USA | Retrospective cohort | 122 | – | – | – | – | 339 | – | – | – | – | – | 36 months |
Schlegelmilch et al. (2017) | Canada | Retrospective case control | 26 | – | – | – | – | 6 | – | – | – | – | – | 12 months |
Seol et al. (2015) | Korea | Retrospective cohort | 147 | 41.9 | 112:35 | 23.7 | 54/41/5/0 | 59 | 46.3 | 45:14 | 23.8 | 46/46/8/0 | 18.7Â months | 34.4Â months |
Shih et al. (1985) | China | Retrospective cohort | 20 | 40.7 | 17:3 | – | – | 15 | 46.6 | 13:2 | – | – | – | 365–530 days |
Taheriazam et al. (2019) | Iran | Randomized clinical trial | 90 | 59.3 | 59:31 | 28.4 | score 1 or 2 | 90 | 59.1 | 52:38 | 28.7 | score 1 or 2 | 6–12 months | 24 months |
Tan et al. (2019) | China | Retrospective cohort | 256 | 52 | 143:113 | 23.8 | 41/49/8/2 | 256 | 54.9 | 120:136 | 23.8 | 38/54/7/1 | – | 3 months |
Triantafyllopoulos et al. (2016) | USA | Retrospective cohort | 1808 | 56.3 | 930:878 | – | – | 4842 | 62.3 | 1995:2847 | – | – | 249–1710 days | 112.6 months |
Villa et al. (2019) | USA | Retrospective cohort | 61 | 55.4 | 40:21 | 27.5 | 15/69/16/0 | 143 | 63.1 | 63:80 | 27.7 | 7/69/24/0 | 461 | – |